Subscribe
Subscribe

Immunology

Biomedical/pharma, Immunology, Oncology

Fund+ Portfolio Company Tubulis to be Acquired by Gilead

• Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments • Tubulis’ next-generation ADC platform includes its clinically validated linker-payload technology • The acquisition includes Tubulis’ lead asset TUB-040, a NaPi2b-targeting ADC for ovarian cancer and other solid tumors

MeSH Counter: A Tool to Track Biomedical Research Trends

Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.

Belgian Biotech Agomab Debuts on Nasdaq with a $200 Million IPO

Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.

ATB Therapeutics: Antibody Seeker Missiles for Cancer and Autoimmune Diseases

Antibodies have long held promise as a ‘magic bullet’ for cancer therapies, yet many antibody-drug conjugates face issues with toxicity and resistance. Belgian startup ATB Therapeutics is producing a new type of weaponized antibodies, using plants as mini factories for safe, effective cancer and autoimmune treatments.

Called to Science with Bart Lambrecht: From medicine to finding focus in fly fishing

VIB’s podcast Called to Science is back for a second season—a series where science journalist Brad Van Paridon sits with researchers to go beyond the science: exploring the passion, setbacks, and big questions that motivate them. In this episode, Bart Lambrecht—director of the VIB Center for Inflammation Research and a practicing physician at Ghent University Hospital—dives into the overlaps between treating patients, running a lab, and the fascination that drives him forward.

Trio of scientists win Nobel Prize for immune system regulation

Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi have been awarded the Nobel Prize in Physiology or Medicine 2025 for their groundbreaking discoveries in peripheral immune tolerance—how the immune system uses regulatory T cells to prevent other immune cells from attacking our own body. Their work laid the foundation for a new field of research and spurred the development of treatments for cancer and autoimmune diseases.

ATMPs & Nuclear Medicine: Wallonia’s strengths on display with BioWin on Tour

Buses full of innovators, lab doors wide open and conversations to spark collaboration—that was the vibe for BioWin on Tour on 24 September 2025, co-organized with AWEX. It was a whirlwind visit, with fifty international delegates from nine countries visiting two of Wallonia’s flagship science hubs—LégiaPark and BioPark Charleroi—discovering the region’s twin strengths of ATMPs and nuclear medicine.

From startup survivor to sector leader: MRM Health CEO’s advice for fellow entrepreneurs at BioWin Days

In the space of just a few years, MRM Health has transformed from a challenger in the emerging microbiome therapeutics field to a global forerunner. CEO Sam Possemiers has steered the Belgian company through the rollercoaster of scientific uncertainty and investor skepticism to reach what he calls the “slope of enlightenment.” Now, with late-stage clinical trials ahead and a new important funding round within reach, Possemiers is sharing his lessons-learned with other biotech CEOs.

Belgian research pushes the boundaries of coronavirus treatment to prevent the next pandemic

According to the World Health Organization (WHO) SARS-CoV-2 is experiencing a resurgence, with the risk of future outbreaks from emerging variants remaining substantial. To stay ahead of the curve, continued investment in both preventative measures and novel therapies is vital. Groundbreaking Belgian research is leading the way with high-potential compounds targeting SARS-CoV-2, offering a promising new avenue for treatment and pandemic preparedness.

Beyond gluten-free: a hopeful future for those who suffer from Celiac disease

Gluten-free dietary products contain more sugar and fats but fewer nutrients and are generally more expensive. A gluten-free diet can even lead to social isolation and stigmatization. Scientists are thus looking for a way that allows people with celiac gluten intolerance disease to enjoy the benefits of gluten in a safe manner.

Muna Therapeutics: hopeful solutions for memory loss

Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones.

V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Coave Therapeutics: redecorating viral vectors for improved gene therapies

Coave Therapeutics is a French biotech developing gene therapies for neurodegenerative and ocular diseases. The company has developed a technology platform that can be used to redecorate the outer surface of viruses, creating gene therapy vectors that are better at accurately delivering healthy genes to the right target cells, including neurons in the deep brain tissue. By combining this vector technology with transgenes restoring natural cell cleaning pathways, the company has created a pipeline of therapies for both genetically and non-genetically defined neurodegenerative diseases, such as Parkinson’s Disease, Multiple System Atrophy (MSA), and Amyotrophic Lateral Sclerosis (ALS).

Cancer vaccines: not only treating tumors, but preventing them too

The COVID-19 pandemic has brought vaccines back into the drug development spotlight, and mRNA vaccines are stealing the show with sales of USD 54.4 billion in 2021 alone. Few know that the developers of the mRNA COVID-19 vaccines actually drew upon years of experience attempting to develop cancer vaccines. This approach goes back several decades, and although the field has to date seen limited success, it has nevertheless witnessed a renewed interests in recent years. We examine the latest trends in cancer vaccine development, and where the opportunities lie for the future of the industry.